Share on StockTwits

Stock analysts at Jefferies Group upped their target price on shares of ResMed (NYSE:RMD) from $40.00 to $42.00 in a report issued on Friday. The firm currently has a “hold” rating on the stock. Jefferies Group’s price objective suggests a potential downside of 15.46% from the stock’s previous close.

Shares of ResMed (NYSE:RMD) opened at 49.68 on Friday. ResMed has a 52 week low of $41.52 and a 52 week high of $57.34. The stock’s 50-day moving average is $50.70 and its 200-day moving average is $47.72. The company has a market cap of $6.972 billion and a P/E ratio of 22.70.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.64 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.66 by $0.02. The company had revenue of $415.20 million for the quarter, compared to the consensus estimate of $433.42 million. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was up .1% on a year-over-year basis. Analysts expect that ResMed will post $2.49 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Thursday, September 18th. Stockholders of record on Thursday, August 21st will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 2.25%. The ex-dividend date is Tuesday, August 19th. This is a boost from ResMed’s previous quarterly dividend of $0.25.

RMD has been the subject of a number of other recent research reports. Analysts at Deutsche Bank downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday, July 3rd. They now have a $52.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Wednesday, June 11th. They now have a $55.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. upgraded shares of ResMed from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $46.01.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.